← Back to Portfolio

Proteon Therapeutics

Proteon is developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company’s lead product, a recombinant human elastase, is in late-stage trials to prolong the patency and reduce the failure of haemodialysis vascular access in patients with chronic kidney disease. The company went public in October 2014.

LocationWaltham, Massachusetts
CEOTimothy Noyes
PartnerTim Haines
Websitewww.proteontherapeutics.com